- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Psyence Biomedical fell on 75-to-1 share consolidation and Nasdaq delisting notice | 3 | Seeking Alpha | ||
| Di | Psyence Biomedical Ltd.: Psyence Biomedical Announces Results from Annual and Special General Meeting, Share Consolidation and Receipt of Additional Staff Determination from Nasdaq | 59 | GlobeNewswire (Europe) | NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) ("Psyence Biomed" or the "Company") today announced the voting results for each of the matters presented at the Company's... ► Artikel lesen | |
| Di | PSYENCE BIOMEDICAL LTD. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 01.11. | PSYENCE BIOMEDICAL LTD. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 30.10. | PSYENCE BIOMEDICAL LTD. - F-1, Registration statement for certain foreign private issuers | 1 | SEC Filings | ||
| 25.10. | Psyence Group Inc.: Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Recruitment of Second Clinical Trial Site for Ongoing Phase IIb Clinical Trial of Nature-Derived Psilocybin for Adjustment Disorder in Palliative Care | 3 | GlobeNewswire (USA) | ||
| 24.10. | Psyence Biomed erweitert australischen Standort für Psilocybin-Studie | 1 | Investing.com Deutsch | ||
| 24.10. | Psyence Biomedical Ltd.: Psyence Biomed Announces Recruitment of Second Clinical Trial Site for Ongoing Phase IIb Clinical Trial of Nature-Derived Psilocybin for Adjustment Disorder in Palliative Care | 49 | GlobeNewswire (Europe) | Empax Center brings significant expertise in clinical trial execution for mental health and neurological conditions Psyence Biomed on track to begin recruitment this quarter, and to announce Adjustment... ► Artikel lesen | |
| PSYENCE BIOMEDICAL Aktie jetzt für 0€ handeln | |||||
| 23.10. | Psyence Biomedical Sets Annual General Meeting for November 12 | 3 | Investing.com | ||
| 23.10. | PSYENCE BIOMEDICAL LTD. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 17.10. | Psyence Biomedical Ltd.: Psyence Biomed Provides Progress Update on PsyLabs E.U. Good Manufacturing Practices (GMP) Certified Active Pharmaceutical Ingredient (API) Development | 83 | GlobeNewswire (Europe) | NEW YORK, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) ("Psyence Biomed" or the "Company") is pleased to provide an update on its previously-announced pending strategic... ► Artikel lesen | |
| 15.10. | Psyence Group Inc: Psyence Group, Psyence Biomed enter debt swap deal | 3 | Stockwatch | ||
| 14.10. | Psyence Group Inc.: Psyence Group Enters into Debt-for-Equity Swap Agreement with its NASDAQ-Listed Associate, Psyence Biomedical | 112 | GlobeNewswire (Europe) | TORONTO, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Psyence Group Inc ("Psyence Group" or the "Company") (CSE: PSYG) hereby announces that it has entered into a debt-for-equity swap agreement (the "Debt Swap... ► Artikel lesen | |
| 08.10. | PSYENCE BIOMEDICAL LTD. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 04.10. | Psyence Biomed halts Clairvoyant Therapeutics acquisition | 2 | Investing.com | ||
| 04.10. | Psyence Biomedical to not proceed with Clairvoyant acquisition | 1 | Seeking Alpha | ||
| 04.10. | Psyence Biomed stoppt Übernahme von Clairvoyant Therapeutics | 2 | Investing.com Deutsch | ||
| 04.10. | Psyence Biomedical Ltd.: Psyence Biomed Provides Update on Previously Announced Acquisition of Clairvoyant | 120 | GlobeNewswire (Europe) | NEW YORK, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) ("Psyence Biomed" or the "Company"), a developer of psilocybin-based therapeutics, today provided an update on its... ► Artikel lesen | |
| 02.10. | Psyence Biomedical files to sell 10.9M common shares for holders. | 2 | Seeking Alpha | ||
| 02.10. | PSYENCE BIOMEDICAL LTD. - F-1, Registration statement for certain foreign private issuers | 1 | SEC Filings |
Seite:
1 2 3 4 Weiter >>
66 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| AVIDITY BIOSCIENCES | 42,180 | 0,00 % | Avidity Biosciences jumps 16%; reaches all-time high | ||
| EVOTEC | 10,420 | -0,48 % | Evotec Aktie: Droht der Test des Jahrestiefs oder gelingt Kurswende? | Nach dem erfolglosen Versuch der Evotec Aktie, die Widerstandszone bei 8,27/8,37 bis 8,54 Euro zu testen, verzeichnete der Aktienkurs des Hamburger Biotech-Unternehmens am Freitag ein Minus von fast... ► Artikel lesen | |
| ADMA BIOLOGICS | 19,040 | 0,00 % | Adma Biologics Aktie: Erholung nach starkem Kursrückgang | ||
| ARCELLX | 87,83 | 0,00 % | Arcellx-Direktorin Kavita Patel verkauft Aktien im Wert von 159.495 US-Dollar | ||
| PRAXIS PRECISION MEDICINES | 71,76 | 0,00 % | Praxis Precision Medicines' Chefjurist verkauft Aktien im Wert von 660.827 US-Dollar | ||
| ITEOS THERAPEUTICS | 8,230 | 0,00 % | iTeos Therapeutics Inc.: iTeos verkündet Finanzergebnisse für das dritte Quartal 2024 und gibt aktuelle Geschäftsinformationen bekannt | - EMA erteilt Freigabe zur Weiterentwicklung
von Belrestotug 400 mg + Dostarlimab als empfohlene Phase-III-Dosis und Aktivierung der klinischen Prüfzentren für GALAXIES Lung-301 in der EU- Zwischenergebnisse... ► Artikel lesen | |
| CG ONCOLOGY | 32,895 | 0,00 % | CG Oncology (NASDAQ:CGON) Posts Quarterly Earnings Results, Beats Estimates By $0.06 EPS | ||
| COGENT BIOSCIENCES | 8,900 | 0,00 % | Cogent Biosciences (NASDAQ:COGT) Issues Earnings Results | ||
| 4D MOLECULAR THERAPEUTICS | 8,830 | 0,00 % | 4D Molecular Therapeutics, Inc.: 4DMT Reports Third Quarter 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones | Presented positive interim data for 4D-150 in wet age-related macular degeneration (wet AMD) from PRISM Phase 1/2 clinical trial highlighting robust and durable clinical activity across diverse patient... ► Artikel lesen | |
| SPRINGWORKS THERAPEUTICS | 36,450 | 0,00 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights | - Achieved $49.3 million in OGSIVEO® (nirogacestat) net product revenue in the third quarter - - Long-term follow-up data from the Phase 3 DeFi trial of nirogacestat in adults with desmoid tumors... ► Artikel lesen | |
| QIAGEN | 38,795 | -0,98 % | Qiagen - Zarte Ansätze von höherer Nachfrage | Qiagen überzeugt im dritten Quartal mit den stärksten Ergebnissen seit Auftaktquartal 2022. Zwei zentrale Entwicklungen lassen auf weiteres Wachstum hoffen und unterstreichen das Potenzial des Labordienstleisters.... ► Artikel lesen | |
| LONGBOARD PHARMACEUTICALS | 59,68 | 0,00 % | Longboard Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Updates | LA JOLLA, Calif.--(BUSINESS WIRE)--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 34,175 | 0,00 % | Structure Therapeutics reports Q3 results | ||
| NUVALENT | 86,90 | 0,00 % | Nuvalent, Inc.: Nuvalent Highlights Corporate and Pipeline Achievements, Reiterates Key Anticipated Milestones, and Reports Third Quarter 2024 Financial Results | Achievement of all anticipated 2024 milestones and accelerated development timelines reinforce progress on OnTarget 2026 operating plan towards first approved product... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 44,860 | 0,00 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports Third Quarter and Year-to-Date 2024 Financial Results and Recent Business Achievements | Generated $48.1 million in XDEMVY® net product sales driven by more than 41,400 bottles delivered to patients in the third quarter Strengthened payer coverage highlighted by securing the two remaining... ► Artikel lesen |
Das Unternehmen PSYENCE BIOMEDICAL LTD kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 0,051 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PSYENCE BIOMEDICAL LTD finden Sie auf Wallstreet Online.
